Following our recent announcement about the significant financial impact caused by COVID-19, we’ve taken the difficult decision to pause some of our planned activity, including the 2020 Accelerator Award funding call (Round 5).
The Accelerator Award remains an extremely important funding stream for us and our funding partners, AIRC and FC AECC, supporting impactful and high-quality research projects. We collectively remain fully committed to the scheme and our partnership, which has enabled collaborative cancer research to flourish across Europe.
We will continue to support our existing portfolio of awards and will be reviewing the financial situation with a view to re-starting the scheme when we can. Subject to our financial position, we hope to be able to re-open the Accelerator Awards to applications in 12 – 18 months.
The purpose of the Accelerator Award is to enable progress in translational cancer research through the development of tools, platforms and skills that form the foundations of such research. We fund ambitious programmes which typically have multiple strands. These may include:
- Producing datasets, tissue banks, cell lines or models
- Developing methods, protocols, software and standards
- Training, skills and knowledge sharing
Cancer is a global health issue, which is why we partnered with AIRC Foundation for Cancer Research and Fundación Científica de la Asociación Española Contra el Cáncer, the principal cancer research charities in Italy and Spain respectively. Our Accelerator Award is helping researchers share skills and resources for maximum patient benefit across borders.